{
  "id": "mhgap#risk_safety_930c6049",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "92 CMH 3 CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Follow-up 3 MONITOR PHARMACOLOGICAL TREATMENT AS APPLICABLE Additional monitoring if the adolescent Additional monitoring if the child has has been prescribed fluoxetine been prescribed methylphenidate Record prescription and administration details. Record prescription and administration details. Weekly for the first month, then every month: Monitor potential for misuse and diversion. monitor for reported side-effects and changes in mood and Every three months: monitor/record height, weight, blood other symptoms. pressure, reported side-effects, and changes in behaviour. Consult specialist if you identify severe medication side- Consult specialist if you observe medication side-effects effects or adverse events (e.g. new or worsening suicidal (e.g. failure to make expected gains in weight and height, thoughts, suicidal or self-harming behaviour, agitation, increased blood pressure, agitation, anxiety, and severe irritability, anxiety or insomnia). insomnia). Advise the adolescent to continue the medication even if After one year of treatment: Consult specialist regarding they feel better. The medication should be continued for the continuation of methylphenidate. 9-12 months after the symptoms have resolved to reduce the risk of relapse. Advise against suddenly stopping the medication. If symptoms have been resolved for 9-12 months: Discuss with adolescent and carer risks and benefits to taper off medication. Reduce treatment gradually over minimum 4 weeks, monitor closely for symptom recurrence. DEMENTIA Dementia is a chronic and progressive syndrome due to changes in emotional control, social behaviour, or motivation. People with",
  "gloss_vi": "92 cmh 3 child & adolescent mental & behavioural disorders follow-up 3 monitor pharmacological treatment as applicable additional monitoring if the adolescent additional monitoring if the child has has been prescribed fl...",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "life_topics": [
      "sleep"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn 92 CMH 3 CHILD & ADOLESCENT MENTAL & BEHAVIOURAL DISORDERS Follow-up 3 MONITOR PHARMACOLOGICAL TREATMENT AS APPLICABLE Additional monitoring if the adolescent Additional monitoring if the child has has been prescribed fluoxetine been prescribed methylphenidate Record prescription and administration details. Record prescription and administration details. Weekly for the first month, then every month: Monitor potential for misuse and diversion. monitor for reported side-effects and changes in mood and Every three months: monitor/record height, weight, blood other symptoms. pressure, reported side-effects, and changes in behaviour. Consult specialist if you identify severe medication side- Consult specialist if you observe medication side-effects effects or adverse events (e.g. new or worsening suicidal (e.g. failure to make expected gains in weight and height, thoughts, suicidal or self-harming behaviour, agitation, increased blood pressure, agitation, anxiety, and severe irritability, anxiety or insomnia). insomnia). Advise the adolescent to continue the medication even if After one year of treatment: Consult specialist regarding they feel better. The medication should be continued for the continuation of methylphenidate. 9-12 months after the symptoms have resolved to reduce the risk of relapse. Advise against suddenly stopping the medication. If symptoms have been resolved for 9-12 months: Discuss with adolescent and carer risks and benefits to taper off medication. Reduce treatment gradually over minimum 4 weeks, monitor closely for symptom recurrence. DEMENTIA Dementia is a chronic and progressive syndrome due to changes in emotional control, social behaviour, or motivation. People with 92 cmh 3 child & adolescent mental & behavioural disorders follow-up 3 monitor pharmacological treatment as applicable additional monitoring if the adolescent additional monitoring if the child has has been prescribed fl..."
}